Welcome to our dedicated page for Rani Therapeutics Holdings news (Ticker: RANI), a resource for investors and traders seeking the latest updates and insights on Rani Therapeutics Holdings stock.
Rani Therapeutics Holdings, Inc. (Nasdaq: RANI) is a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs through its proprietary RaniPill® capsule platform. The RANI news page on Stock Titan aggregates company press releases, market announcements and regulatory updates so readers can follow how this oral biologics platform is progressing through preclinical and clinical development.
According to the company’s disclosures, recent news has highlighted pipeline milestones, such as preclinical data and the initiation of a Phase 1 clinical trial for RT-114, an orally administered RaniPill capsule containing a GLP-1/GLP-2 dual agonist (PG-102) being developed for the treatment of obesity. Rani has also reported preclinical data on oral semaglutide (RT-116) and on oral delivery of a bispecific GLP-1/GLP-2 receptor agonist via RaniPill, with results described as comparable in bioavailability and weight loss to subcutaneous injections in animal models.
Investors and observers can use this news feed to track strategic collaborations and financings, including Rani’s Collaboration and License Agreement with Chugai Pharmaceutical Co., Ltd. for an oral product combining RaniPill HC with a rare disease antibody, and its collaboration with ProGen Co., Ltd. for RT-114 in weight management. The company’s announcements also cover private placements, registered offerings, warrant transactions and related board changes tied to institutional investors.
In addition, Rani’s news includes quarterly financial results and corporate updates, where management discusses cash runway expectations, research and development spending and progress across its oral biologics pipeline. For anyone following RANI stock or the evolution of oral delivery technologies for biologics, this page offers a centralized view of company-generated news, from clinical trial plans to collaboration agreements and capital markets activity.
Rani Therapeutics (Nasdaq: RANI) priced an oversubscribed private placement expected to raise approximately $60.3 million in gross proceeds, with closing targeted on or about October 21, 2025. The financing includes 42,633,337 shares at $0.48 each and pre-funded warrants for up to 82,366,667 shares at $0.4799 each, plus accompanying warrants to purchase up to 125,000,004 shares exercisable upon stockholder approval.
The company said net proceeds, together with a $10.0 million upfront payment and an expected $18.0 million technology-transfer milestone from a Chugai collaboration, are expected to fund operations into 2028. Samsara and Anomaly will each gain the right to designate a board member; Avenue converted $6.0 million of debt into equity as part of the transaction.
Rani Therapeutics (Nasdaq: RANI) announced a Collaboration and License Agreement with Chugai on October 17, 2025 to develop an oral product using RaniPill and a Chugai rare‑disease antibody.
Key terms: $10 million upfront, up to $75 million in technology transfer and development milestones, up to $100 million in sales milestones, single‑digit royalties, and an option for Chugai to add up to five additional targets — bringing total potential deal value to $1.085 billion. Rani also announced an oversubscribed $60.3 million PIPE led by Samsara BioCapital; net proceeds plus upfront and an expected $18.0 million technology transfer milestone are expected to fund operations into 2028.
Rani Therapeutics (NASDAQ:RANI) reported Q2 2025 financial results and corporate updates. The company announced a strategic research collaboration with Chugai for two undisclosed molecules and presented promising preclinical data for RT-114, their novel oral bispecific GLP-1/GLP-2 receptor agonist for obesity treatment.
Financial highlights include a $4.3 million warrant inducement transaction and a $3.0 million registered direct offering. Cash position stood at $10.2 million as of June 30, 2025, down from $27.6 million at year-end 2024. The company reported a reduced net loss of $11.2 million compared to $13.4 million in Q2 2024, with decreased R&D and G&A expenses.
Rani plans to initiate a Phase 1 clinical trial for RT-114 in obesity treatment during H2 2025.
Rani Therapeutics (NASDAQ: RANI), a clinical-stage biotherapeutics company, has announced a $3.0 million registered direct offering of its Class A common stock and pre-funded warrants. The company will sell 4,354,000 shares at $0.40 per share and pre-funded warrants for 3,146,000 shares at $0.3999 to a single institutional investor.
The offering, expected to close around July 16, 2025, is being conducted through Maxim Group LLC as the sole placement agent. The pre-funded warrants will have an exercise price of $0.0001 per share. The offering is made pursuant to an effective shelf registration statement, with proceeds subject to placement agent fees and offering expenses.
Rani Therapeutics (NASDAQ: RANI) announced it will present preclinical data for its RaniPill® capsule at ENDO 2025 in San Francisco. The presentation will showcase research demonstrating bioequivalence between oral delivery of a bispecific GLP-1/GLP-2 receptor agonist (PG-102) using their robotic pill (RT-114) and traditional subcutaneous injection in canines.
The poster presentation, titled "Oral Delivery of a Bispecific GLP-1/GLP-2 Receptor Agonist (PG-102) via a Robotic Pill (RT-114)," will be presented by Dr. Anvesh Dasari on July 14, 2025, from 12:00 PM to 1:30 PM PT, as part of the session on adipose tissue, appetite, and obesity therapeutic advances.
Rani Therapeutics (NASDAQ: RANI) has announced a Research Agreement with Chugai Pharmaceutical to evaluate the feasibility of applying Rani's oral delivery technology to Chugai's antibodies. The agreement, signed on August 13, 2024, covers two molecules with undisclosed targets. Initial analysis shows the RaniPill® delivery system achieved comparable bioavailability to subcutaneous delivery for both studied molecules.
Rani has previously evaluated 19 diverse molecules preclinically and completed three Phase 1 clinical trials with the RaniPill® capsule. The collaboration aims to leverage Rani's expertise in developing oral antibodies, peptides, and large proteins with high bioavailability alongside Chugai's technology-driven drug discovery approach.
Rani Therapeutics (NASDAQ: RANI) has reported its Q4 and full year 2024 financial results, highlighting significant progress in its oral biologics delivery platform. The company demonstrated successful preclinical results for RT-114, a GLP-1/GLP-2 dual agonist showing bioequivalence to subcutaneous administration, and successful oral delivery of semaglutide via the RaniPill® capsule.
Financial highlights include:
- Cash position of $27.6 million as of December 31, 2024
- Contract revenue of $1.0 million for Q4 and full year 2024
- R&D expenses decreased to $26.7 million in 2024 from $39.6 million in 2023
- Net loss of $56.6 million for 2024, improved from $67.9 million in 2023
The company completed two equity offerings in 2024 raising approximately $20.0 million in gross proceeds. Rani expects its current cash position to fund operations into Q3 2025 and plans to initiate a Phase 1 study of RT-114 for obesity treatment in mid-2025.
Rani Therapeutics (RANI) announced promising preclinical data for RT-114, their oral GLP-1/GLP-2 dual agonist delivered via RaniPill® capsule. The study demonstrated bioequivalence with subcutaneously administered PG-102, achieving 111% relative bioavailability and comparable pharmacokinetic profiles.
Key findings from the canine study include:
- 90% delivery success rate (9 out of 10 canines)
- Identical average peak weight loss of 6.7% in both oral and subcutaneous groups
- Well-tolerated with no safety concerns
Previous Phase 1 trials of subcutaneous PG-102 showed weight loss in obese patients, averaging 4.8% and reaching up to 8.7% after five weeks. The company plans to initiate a Phase 1 clinical trial for RT-114 in mid-2025, targeting obesity treatment with a convenient oral dosing regimen.
Rani Therapeutics (Nasdaq: RANI), a clinical-stage biotherapeutics company specializing in oral delivery of biologics and drugs, has scheduled the release of its fourth quarter and full year 2024 financial results on Monday, March 31, 2025, after market close.
The company will host a conference call and webcast at 4:30 p.m. ET / 1:30 p.m. PT on the same day. Interested parties can access the webcast through the 'Investors' section of Rani's website at www.ranitherapeutics.com. A replay will be available in the investor relations section following the call.